Details of the Drug

General Information of Drug (ID: DM7NKEV)

• Drug Name: Thioguanine
• Synonyms: 6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Approved	[1], [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 167.19
  Topological Polar Surface Area (xlogp); -0.1
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 15.4 mL/min/kg [4]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 24.35 hours [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.89 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.2 mg/mL [3]
• Chemical Identifiers:
  Formula: C5H5N5S
  IUPAC Name: 2-amino-3,7-dihydropurine-6-thione
  Canonical SMILES: C1=NC2=C(N1)C(=S)N=C(N2)N
  InChI: InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
  InChIKey: WYWHKKSPHMUBEB-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2723601
  ChEBI ID: CHEBI:9555
  CAS Number: 154-42-7
  DrugBank ID: DB00352
  TTD ID: D02ZXM
  VARIDT ID: DR00510
  INTEDE ID: DR1597
  ACDINA ID: D00671

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inosine-5'-monophosphate dehydrogenase (IMPDH)	TTCAQMW	NOUNIPROTAC	Intercalator	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)	DT4YL5R	S28A3_HUMAN	Substrate	[6]
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[7]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Hypoxanthine phosphoribosyltransferase (HPRT1)	DEVXTP5	HPRT_HUMAN	Substrate	[9]
Thiopurine methyltransferase (TPMT)	DEFQ8VO	TPMT_HUMAN	Substrate	[10]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Thioguanine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Tagraxofusp	DM9HQ5U	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tagraxofusp.	Acute myeloid leukaemia [2A60]	[47]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[47]

Coadministration of a Drug Treating the Disease Different from Thioguanine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[48]
Tretinoin	DM49DUI	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tretinoin.	Acne vulgaris [ED80]	[47]
Isotretinoin	DM4QTBN	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Isotretinoin.	Acne vulgaris [ED80]	[47]
Nicotinamide	DMUPE07	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Nicotinamide.	Acquired cutaneous blood vessel malformation [EF20]	[47]
Pioglitazone	DMKJ485	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Pioglitazone.	Acute diabete complication [5A2Y]	[47]
Chlorzoxazone	DMCYVDT	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Chlorzoxazone.	Acute pain [MG31]	[47]
Oxandrolone	DMU9MYJ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Oxandrolone.	Alcoholic liver disease [DB94]	[47]
Tacrine	DM51FY6	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tacrine.	Alzheimer disease [8A20]	[47]
Inotersen	DMJ93CT	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Inotersen.	Amyloidosis [5D00]	[47]
Dronedarone	DMA8FS5	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Dronedarone.	Angina pectoris [BA40]	[47]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[49]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Oxymetholone.	Aplastic anaemia [3A70]	[47]
Voriconazole	DMAOL2S	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Voriconazole.	Aspergillosis [1F20]	[47]
Posaconazole	DMUL5EW	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Posaconazole.	Aspergillosis [1F20]	[47]
Zafirlukast	DMHNQOG	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Zafirlukast.	Asthma [CA23]	[47]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Thioguanine and Roflumilast.	Asthma [CA23]	[50]
Zileuton	DMVRIC2	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Zileuton.	Asthma [CA23]	[47]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Clavulanate	DM2FGRT	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Clavulanate.	Bacterial infection [1A00-1C4Z]	[47]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[51]
Clarithromycin	DM4M1SG	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[47]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[47]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[51]
ABT-492	DMJFD2I	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[51]
Levofloxacin	DMS60RB	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[47]
Troleandomycin	DMUZNIG	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Troleandomycin.	Bacterial infection [1A00-1C4Z]	[47]
Minocycline	DMVN5OH	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Minocycline.	Bacterial infection [1A00-1C4Z]	[47]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Telithromycin	DMZ4P3A	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[47]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Thioguanine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[52]
Lomustine	DMMWSUL	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Lomustine.	Brain cancer [2A00]	[47]
Lapatinib	DM3BH1Y	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Lapatinib.	Breast cancer [2C60-2C6Y]	[47]
LY2835219	DM93VBZ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and LY2835219.	Breast cancer [2C60-2C6Y]	[47]
Pralatrexate	DMAO80I	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Pralatrexate.	Breast cancer [2C60-2C6Y]	[47]
Tucatinib	DMBESUA	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tucatinib.	Breast cancer [2C60-2C6Y]	[47]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[47]
Bosutinib	DMTI8YE	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Bosutinib.	Breast cancer [2C60-2C6Y]	[47]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[47]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[47]
Grepafloxacin	DMGLX0T	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Grepafloxacin.	Bronchitis [CA20]	[51]
Atorvastatin	DMF28YC	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Atorvastatin.	Cardiovascular disease [BA00-BE2Z]	[47]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[47]
Macitentan	DMP79A1	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Macitentan.	Cardiovascular disease [BA00-BE2Z]	[47]
Chenodiol	DMQ8JIK	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Chenodiol.	Cholelithiasis [DC11]	[47]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Phenylbutazone.	Chronic pain [MG30]	[47]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ketoprofen.	Chronic pain [MG30]	[47]
Regorafenib	DMHSY1I	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Regorafenib.	Colorectal cancer [2B91]	[47]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Oxaliplatin.	Colorectal cancer [2B91]	[47]
Intedanib	DMSTA36	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Intedanib.	Colorectal cancer [2B91]	[47]
Pasireotide	DMHM7JS	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Pasireotide.	Cushing syndrome [5A70]	[47]
Ivacaftor	DMZC1HS	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ivacaftor.	Cystic fibrosis [CA25]	[47]
Ethanol	DMDRQZU	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ethanol.	Cystitis [GC00]	[47]
Nefazodone	DM4ZS8M	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Nefazodone.	Depression [6A70-6A7Z]	[47]
Duloxetine	DM9BI7M	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Duloxetine.	Depression [6A70-6A7Z]	[47]
Milnacipran	DMBFE74	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Milnacipran.	Depression [6A70-6A7Z]	[47]
Polatuzumab vedotin	DMF6Y0L	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[47]
PMID28454500-Compound-96	DM2A75P	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and PMID28454500-Compound-96.	Discovery agent [N.A.]	[47]
Felbamate	DM1V5ZS	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[47]
Mephenytoin	DM5UGDK	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Mephenytoin.	Epilepsy/seizure [8A61-8A6Z]	[47]
Fosphenytoin	DMOX3LB	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Fosphenytoin.	Epilepsy/seizure [8A61-8A6Z]	[47]
Ethotoin	DMXWOCP	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ethotoin.	Epilepsy/seizure [8A61-8A6Z]	[47]
Carbamazepine	DMZOLBI	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[47]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Cannabidiol.	Epileptic encephalopathy [8A62]	[50]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Mefenamic acid.	Female pelvic pain [GA34]	[47]
Dantrolene	DM1D8XY	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Dantrolene.	Fever [MG26]	[47]
Itraconazole	DMCR1MV	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Itraconazole.	Fungal infection [1F29-1F2F]	[47]
Caspofungin	DMGQIPT	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Caspofungin.	Fungal infection [1F29-1F2F]	[47]
Terbinafine	DMI6HUW	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Terbinafine.	Fungal infection [1F29-1F2F]	[47]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ketoconazole.	Fungal infection [1F29-1F2F]	[47]
Atovaquone	DMY4UMW	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Atovaquone.	Fungal infection [1F29-1F2F]	[47]
Sunitinib	DMCBJSR	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[47]
Lamivudine	DMI347A	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Lamivudine.	Hepatitis virus infection [1E50-1E51]	[47]
177Lu-DOTATATE	DMT8GVU	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[47]
Isoniazid	DM5JVS3	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Isoniazid.	HIV-infected patients with tuberculosis [1B10-1B14]	[47]
Rifampin	DMA8J1G	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[47]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[47]
Zidovudine	DM4KI7O	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Zidovudine.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Tipranavir	DM8HJX6	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Emtricitabine	DMBMUWZ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Emtricitabine.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Zalcitabine	DMH7MUV	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Abacavir	DMMN36E	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Abacavir.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Darunavir	DMN3GCH	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Darunavir.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Maraviroc	DMTL94F	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Ritonavir	DMU764S	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ritonavir.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Simvastatin	DM30SGU	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Simvastatin.	Hyper-lipoproteinaemia [5C80]	[47]
Fluvastatin	DM4MDJY	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Fluvastatin.	Hyper-lipoproteinaemia [5C80]	[47]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[47]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Thioguanine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[53]
Rosuvastatin	DMMIQ7G	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Rosuvastatin.	Hyper-lipoproteinaemia [5C80]	[47]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Thioguanine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[54]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Thioguanine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[55]
Cerivastatin	DMXCM7H	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Cerivastatin.	Hyper-lipoproteinaemia [5C80]	[47]
Moexipril	DM26E4B	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Moexipril.	Hypertension [BA00-BA04]	[47]
Trandolapril	DM4L6EU	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Trandolapril.	Hypertension [BA00-BA04]	[47]
Methyldopa	DM5I621	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Methyldopa.	Hypertension [BA00-BA04]	[47]
Fosinopril	DM9NJ52	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Fosinopril.	Hypertension [BA00-BA04]	[47]
Benazepril	DMH1M9B	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Benazepril.	Hypertension [BA00-BA04]	[47]
Labetalol	DMK8U72	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Labetalol.	Hypertension [BA00-BA04]	[47]
Enalapril	DMNFUZR	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Enalapril.	Hypertension [BA00-BA04]	[47]
Perindopril	DMOPZDT	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Perindopril.	Hypertension [BA00-BA04]	[47]
Quinapril	DMR8H31	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Quinapril.	Hypertension [BA00-BA04]	[47]
Lisinopril	DMUOK4C	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Lisinopril.	Hypertension [BA00-BA04]	[47]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[47]
Pirfenidone	DM6VZFQ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Pirfenidone.	Idiopathic interstitial pneumonitis [CB03]	[47]
Vitamin B3	DMQVRZH	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Vitamin B3.	Inborn lipid metabolism error [5C52]	[47]
Givosiran	DM5PFIJ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[47]
Febuxostat	DMDEXQ0	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Febuxostat.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[47]
Balsalazide	DMO091F	Moderate	Decreased metabolism of Thioguanine caused by Balsalazide mediated inhibition of non-CYP450 enzyme.	Indeterminate colitis [DD72]	[56]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[47]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Methotrexate.	Leukaemia [2A60-2B33]	[50]
Testosterone	DM7HUNW	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Testosterone.	Low bone mass disorder [FB83]	[47]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Thioguanine and Denosumab.	Low bone mass disorder [FB83]	[57]
Crizotinib	DM4F29C	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Crizotinib.	Lung cancer [2C25]	[47]
Ceritinib	DMB920Z	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ceritinib.	Lung cancer [2C25]	[47]
Erlotinib	DMCMBHA	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Erlotinib.	Lung cancer [2C25]	[47]
Lurbinectedin	DMEFRTZ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Lurbinectedin.	Lung cancer [2C25]	[47]
Alectinib	DMP1I6Y	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Alectinib.	Lung cancer [2C25]	[47]
BIBW 2992	DMTKD7Q	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and BIBW 2992.	Lung cancer [2C25]	[47]
Pralsetinib	DMWU0I2	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Pralsetinib.	Lung cancer [2C25]	[47]
Capmatinib	DMYCXKL	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Capmatinib.	Lung cancer [2C25]	[47]
Selpercatinib	DMZR15V	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Selpercatinib.	Lung cancer [2C25]	[47]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Sulphadoxine.	Malaria [1F40-1F45]	[47]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[47]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[47]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Idelalisib.	Mature B-cell leukaemia [2A82]	[49]
IPI-145	DMWA24P	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and IPI-145.	Mature B-cell leukaemia [2A82]	[47]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Clofarabine.	Mature B-cell lymphoma [2A85]	[58]
Blinatumomab	DMGECIJ	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Blinatumomab.	Mature B-cell lymphoma [2A85]	[47]
Vincristine	DMINOX3	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Vincristine.	Mature B-cell lymphoma [2A85]	[47]
Mercaptopurine	DMTM2IK	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Mercaptopurine.	Mature B-cell lymphoma [2A85]	[47]
Ponatinib	DMYGJQO	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ponatinib.	Mature B-cell lymphoma [2A85]	[47]
Cytarabine	DMZD5QR	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Cytarabine.	Mature B-cell lymphoma [2A85]	[47]
Arry-162	DM1P6FR	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Arry-162.	Melanoma [2C30]	[47]
Vemurafenib	DM62UG5	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Vemurafenib.	Melanoma [2C30]	[47]
Ipilimumab	DMJTIYK	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ipilimumab.	Melanoma [2C30]	[47]
Dacarbazine	DMNPZL4	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Dacarbazine.	Melanoma [2C30]	[47]
Danazol	DML8KTN	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Danazol.	Menstrual cycle bleeding disorder [GA20]	[47]
Exjade	DMHPRWG	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Exjade.	Mineral absorption/transport disorder [5C64]	[47]
Riluzole	DMECBWN	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Riluzole.	Motor neuron disease [8B60]	[47]
Carfilzomib	DM48K0X	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Carfilzomib.	Multiple myeloma [2A83]	[47]
Panobinostat	DM58WKG	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Panobinostat.	Multiple myeloma [2A83]	[47]
Lenalidomide	DM6Q7U4	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Lenalidomide.	Multiple myeloma [2A83]	[47]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Thioguanine and Thalidomide.	Multiple myeloma [2A83]	[59]
Elotuzumab	DMEYHG9	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Elotuzumab.	Multiple myeloma [2A83]	[47]
Tecfidera	DM2OVDT	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tecfidera.	Multiple sclerosis [8A40]	[47]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Thioguanine and Siponimod.	Multiple sclerosis [8A40]	[60]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Thioguanine and Fingolimod.	Multiple sclerosis [8A40]	[61]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Thioguanine and Ocrelizumab.	Multiple sclerosis [8A40]	[62]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Thioguanine and Ozanimod.	Multiple sclerosis [8A40]	[50]
Fedratinib	DM4ZBK6	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Fedratinib.	Myeloproliferative neoplasm [2A20]	[47]
Nilotinib	DM7HXWT	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[47]
Imatinib	DM7RJXL	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Imatinib.	Myeloproliferative neoplasm [2A20]	[47]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Thioguanine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[63]
Bupropion	DM5PCS7	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Bupropion.	Nicotine use disorder [6C4A]	[47]
Entrectinib	DMMPTLH	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Entrectinib.	Non-small cell lung cancer [2C25]	[47]
Orlistat	DMRJSP8	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Orlistat.	Obesity [5B80-5B81]	[47]
Rofecoxib	DM3P5DA	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Rofecoxib.	Osteoarthritis [FA00-FA05]	[47]
Valdecoxib	DMAY7H4	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Valdecoxib.	Osteoarthritis [FA00-FA05]	[47]
Diclofenac	DMPIHLS	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Diclofenac.	Osteoarthritis [FA00-FA05]	[47]
Naproxen	DMZ5RGV	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Naproxen.	Osteoarthritis [FA00-FA05]	[47]
Etodolac	DM6WJO9	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Etodolac.	Pain [MG30-MG3Z]	[47]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ibuprofen.	Pain [MG30-MG3Z]	[47]
Nabumetone	DMAT2XH	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Nabumetone.	Pain [MG30-MG3Z]	[47]
Piroxicam	DMTK234	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Piroxicam.	Pain [MG30-MG3Z]	[47]
Ketorolac	DMI4EL5	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ketorolac.	Postoperative inflammation [1A00-CA43]	[47]
Bromfenac	DMKB79O	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Bromfenac.	Postoperative inflammation [1A00-CA43]	[47]
ABIRATERONE	DM8V75C	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and ABIRATERONE.	Prostate cancer [2C82]	[47]
Nilutamide	DMFN07X	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Nilutamide.	Prostate cancer [2C82]	[47]
Flutamide	DMK0O7U	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Flutamide.	Prostate cancer [2C82]	[47]
Bicalutamide	DMZMSPF	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Bicalutamide.	Prostate cancer [2C82]	[47]
Acitretin	DM8BKU9	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Acitretin.	Psoriasis [EA90]	[47]
Ambrisentan	DMD1QXW	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Ambrisentan.	Pulmonary hypertension [BB01]	[47]
Bosentan	DMIOGBU	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Bosentan.	Pulmonary hypertension [BB01]	[47]
Axitinib	DMGVH6N	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Axitinib.	Renal cell carcinoma [2C90]	[47]
Sorafenib	DMS8IFC	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Sorafenib.	Renal cell carcinoma [2C90]	[47]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[51]
Sulfadiazine	DMTW3R8	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Sulfadiazine.	Rheumatic fever [1B40]	[47]
Meloxicam	DM2AR7L	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Meloxicam.	Rheumatoid arthritis [FA20]	[47]
Sulindac	DM2QHZU	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Sulindac.	Rheumatoid arthritis [FA20]	[47]
Celecoxib	DM6LOQU	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Celecoxib.	Rheumatoid arthritis [FA20]	[47]
Tocilizumab	DM7J6OR	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tocilizumab.	Rheumatoid arthritis [FA20]	[47]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Thioguanine and Canakinumab.	Rheumatoid arthritis [FA20]	[64]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Oxaprozin.	Rheumatoid arthritis [FA20]	[47]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Thioguanine and Rilonacept.	Rheumatoid arthritis [FA20]	[64]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Flurbiprofen.	Rheumatoid arthritis [FA20]	[47]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Thioguanine and Golimumab.	Rheumatoid arthritis [FA20]	[65]
Sulfasalazine	DMICA9H	Moderate	Decreased metabolism of Thioguanine caused by Sulfasalazine mediated inhibition of non-CYP450 enzyme.	Rheumatoid arthritis [FA20]	[56]
Fenoprofen	DML5VQ0	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Fenoprofen.	Rheumatoid arthritis [FA20]	[47]
Sarilumab	DMOGNXY	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Sarilumab.	Rheumatoid arthritis [FA20]	[47]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Thioguanine and Leflunomide.	Rheumatoid arthritis [FA20]	[54]
Tolmetin	DMWUIJE	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tolmetin.	Rheumatoid arthritis [FA20]	[47]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Thioguanine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[66]
Larotrectinib	DM26CQR	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[47]
PDX-101	DM6OC53	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and PDX-101.	Solid tumour/cancer [2A00-2F9Z]	[47]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[50]
LEE011	DMMX75K	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[47]
Gemcitabine	DMSE3I7	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Gemcitabine.	Solid tumour/cancer [2A00-2F9Z]	[47]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[47]
Disulfiram	DMCL2OK	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Disulfiram.	Substance abuse [6C40]	[47]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Naltrexone.	Substance abuse [6C40]	[67]
Fostamatinib	DM6AUHV	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Fostamatinib.	Thrombocytopenia [3B64]	[47]
Eltrombopag	DMOGFIX	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Eltrombopag.	Thrombocytopenia [3B64]	[47]
Lenvatinib	DMB1IU4	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Lenvatinib.	Thyroid cancer [2D10]	[47]
Methimazole	DM25FL8	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Methimazole.	Thyrotoxicosis [5A02]	[47]
Propylthiouracil	DM6D7N8	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Propylthiouracil.	Thyrotoxicosis [5A02]	[47]
Tizanidine	DMR2IQ4	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Tizanidine.	Tonus and reflex abnormality [MB47]	[47]
Trimetrexate	DMDEA85	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Trimetrexate.	Toxoplasmosis [1F57]	[47]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Thioguanine and Azathioprine.	Transplant rejection [NE84]	[60]
Olsalazine	DMZW9HA	Moderate	Decreased metabolism of Thioguanine caused by Olsalazine mediated inhibition of non-CYP450 enzyme.	Ulcerative colitis [DD71]	[56]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[51]
Nitrofurantoin	DM7PQIK	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Nitrofurantoin.	Urinary tract infection [GC08]	[47]
Sulfamethizole	DMGCHDS	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Sulfamethizole.	Urinary tract infection [GC08]	[47]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[51]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[51]
Elagolix	DMB2C0E	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Elagolix.	Uterine fibroid [2E86]	[47]
Amiodarone	DMUTEX3	Moderate	Increased risk of hepatotoxicity by the combination of Thioguanine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[47]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Thioguanine and Ganciclovir.	Virus infection [1A24-1D9Z]	[60]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Thioguanine and Valganciclovir.	Virus infection [1A24-1D9Z]	[60]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Thioguanine 40 mg tablet	40 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6845).
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9.
• [6] Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15.
• [7] Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57.
• [8] ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
• [9] Qualitative and quantitative difference in mutation induction between carbon- and neon-ion beams in normal human cells. Biol Sci Space. 2003 Dec;17(4):302-6.
• [10] Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
• [11] Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
• [12] Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
• [13] Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
• [14] The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010 Apr;24(4):715-20.
• [15] Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8.
• [16] Ascorbic acid inhibits spinal meningeal catechol-o-methyl transferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology. 1997 Feb;86(2):405-9.
• [17] Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
• [18] Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7.
• [19] Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
• [20] Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402.
• [21] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [22] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [23] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [24] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [25] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [26] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [27] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [28] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [29] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [30] Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
• [31] Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
• [32] ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
• [33] The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
• [34] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [35] Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
• [36] P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
• [37] Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
• [38] Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
• [39] Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
• [40] Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Biophys Chem. 2010 Mar;147(1-2):59-65.
• [41] Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
• [42] Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004 Jul;107(1):63-8.
• [43] Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 1;24(38):5888-96.
• [44] The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury. Shock. 2009 Sep;32(3):258-62.
• [45] US patent application no. 2010,0092,479, Compositions and methods for treatment of viral diseases.
• [46] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2625).
• [47] Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
• [48] European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
• [49] Product Information. Hivid (zalcitabine). Roche Laboratories, Nutley, NJ.
• [50] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [51] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [52] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [53] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [54] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [55] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [56] Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ "Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction [letter comment." Gastroenterology 116 (1999): 1505-6. [PMID: 10391741]
• [57] Product Information. Lonsurf (tipiracil-trifluridine). Taiho Oncology, Inc., Princeton, NJ.
• [58] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [59] Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
• [60] Cerner Multum, Inc. "Australian Product Information.".
• [61] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [62] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [63] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [64] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [65] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [66] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [67] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.